Biopharmaceutics 4.0, advanced pre‐clinical development of mrna‐encoded monoclonal antibodies to immunosuppressed murine models

Abstract

Administration of mRNA against SARS‐CoV‐2 has demonstrated sufficient efficacy, tol-erability and clinical potential to disrupt the vaccination field. A multiple‐arm, cohort randomized, mixed blind, placebo‐controlled study was designed to investigate the in vivo expression of mRNA antibodies to immunosuppressed murine models to conduct efficacy, safety and bioavailability evaluation. Enabling 4.0 tools we reduced animal sacrifice, while interventions were designed com-pliant to HARRP and SPIRIT engagement: (a) Randomization, blinding; (b) pharmaceutical grade formulation, monitoring; (c) biochemical and histological analysis; and (d) theoretic, statistical anal-ysis. Risk assessment molded the study orientations, according to the ARRIVE guidelines. The primary target of this protocol is the validation of the research hypothesis that autologous translation of Trastuzumab by in vitro transcribed mRNA‐encoded antibodies to immunosuppressed animal models, is non‐inferior to classical treatments. The secondary target is the comparative pharmaco-kinetic assessment of the novel scheme, between immunodeficient and healthy subjects. Herein, the debut clinical protocol, investigating the pharmacokinetic/pharmacodynamic impact of mRNA vaccination to immunodeficient organisms. Our design, contributes novel methodology to guide the preclinical development of RNA antibody modalities by resolving efficacy, tolerability and dose regime adjustment for special populations that are incapable of humoral defense.